The CD33 single nucleotide polymorphism (SNP) rs3865444 has been associated with the risk of Alzheimer's disease (AD). Rs3865444 is in linkage disequilibrium with rs12459419 which has been associated with efficacy of an acute myeloid leukemia (AML) chemotherapeutic agent based on a CD33 antibody. We seek to evaluate the extent to which CD33 genetics in AD and AML can inform one another and advance human disease therapy. We have previously shown that these SNPs are associated with skipping of CD33 exon 2 in brain mRNA. Here, we report that these CD33 SNPs are associated with exon 2 skipping in leukocytes from AML patients and with a novel CD33 splice variant that retains CD33 intron 1. Each copy of the minor rs12459419T allele decreases prototypic full-length CD33 expression by about 25% and decreases the AD odds ratio by about 0.10. These results suggest that CD33 antagonists may be useful in reducing AD risk. CD33 inhibitors may include humanized CD33 antibodies such as Lintuzumab which was safe but ineffective in AML clinical trials. Here, we report that Lintuzumab downregulates cell surface CD33 by 80% in phorbol-ester differentiated U937 cells, at concentrations as low as 10 ng/ml. Overall, we propose a model wherein a modest effect on RNA splicing is sufficient to mediate the CD33 association with AD risk and suggest the potential for an anti-CD33 antibody as an AD-relevant pharmacologic agent.
Introduction
Genetic polymorphisms in the myeloid cell surface receptor CD33 have been implicated in Alzheimer's disease (AD) risk and acute myeloid leukemia (AML) treatment efficacy (1) (2) (3) (4) (5) (6) . More specifically, rs3865444 in the CD33 promoter has been associated with AD risk while rs12459419 within CD33 exon 2 has been associated with gemtuzumab ozogamycin (GO) efficacy in AML (1) (2) (3) (4) (5) (6) . We recently reported that these two SNPs are in linkage disequilibrium and associated with exon 2 splicing efficiency in human brain in vivo (7) . We supported these in vivo data with in vitro data that rs12459419 is a functional SNP, modulating exon 2 splicing in a minigene splicing model. This association between the minor rs12459419T allele and increased CD33 exon 2 skipping was subsequently confirmed by others (8) . Since exon 2 encodes the IgV domain which mediates sialic acid binding (9, 10), CD33 lacking exon 2 is likely to have reduced function. Consistent with this possibility, CD33 inhibits Aß phagocytosis in microglial cells but CD33 lacking the IgV-domain has no effect on phagocytosis (11) .
The domain encoded by exon 2 is also critical to the chemotherapeutic actions of GO because this agent depends upon the monoclonal antibody hP67.6, which recognizes an exon 2-encoded epitope (12) . Since CD33 genetics contribute to both AD risk and cancer chemotherapy efficacy, we suggest that an exchange between these two disciplines may be enlightening. In particular, we hypothesize that rs12459419 acts on both AD risk and response to AML chemotherapeutics primarily through its effects on CD33 splicing.
To investigate this hypothesis, we have compared CD33 splicing in brain and AML. We identify a novel CD33 splice variant that retains CD33 intron 1, show that this variant is associated with rs12459419 in both brain and AML, and show that exon 2 splicing in AML cells is also associated with rs12459419. We then compare the CD33 SNP allelic dose response on splicing with the dose response on AD risk, finding that a moderate effect on RNA splicing correlates with significant reduction in AD risk. Lastly, we consider whether a CD33-based biological drug from AML may impact AD research;
we report that Lintuzumab, a humanized anti-CD33 monoclonal antibody that was safe but ineffective in AML (reviewed in (13, 14) ), reduces cell surface CD33 in a robust fashion, suggesting the potential for CD33 antibodies in AD pharmacology.
Results
To elucidate the mechanism underlying the association between CD33 genetics and response to GO treatment in AML patients, we evaluated CD33 splicing in AML cells. The rationale for this study included that rs12459419 is associated with CD33 exon 2 splicing in brain (7, 8) . To assess whether exon 2 shows variable splicing in leukocytes from AML patients, we performed PCR from exons 1 to 3 on cDNA from these cells.
The resultant PCR products were separated on polyacrylamide gels and visualized by fluorescent labeling ( Figure 1A ). This analysis revealed that AML cells express the same CD33 isoforms we detected in human brain, including an isoform lacking exon 2 (D2-CD33) as well as an isoform that retains intron 1 (R1-CD33) (7). CD33 translation is initiated from an ATG within exon 1 and the 351 bp exon 2 encodes the sialic acidbinding IgV domain. Hence, the D2-CD33 isoform encodes a CD33 protein that lacks the sialic acid-binding IgV domain and appears inactive in suppressing microglial activation ( Figure 1B ) (10) . Intron 1 is 62 base pairs in length; consequently, intron 1 retention leads to a frameshift such that the R1-CD33 isoform encodes a prematurely truncated peptide that includes only the signal peptide from CD33 ( Figure 1B ).
We proceeded to evaluate the extent to which rs12459419 was associated with CD33 splicing in two cohorts of cells from AML patients. In a 26 sample cohort from the University of Kentucky, we quantified D2-CD33 expression by qPCR by using a forward primer at the junction of exon 1-3 and a reverse primer in exon 3 ( Figure 1B ). Total CD33 was quantified by using primers in exons 4 and 5. Inspection of the relationship between D2-CD33 and total CD33 suggests that expression of D2-CD33 increases in parallel with total CD33 expression and that individuals carrying the minor rs12459419T allele have increased D2-CD33 expression (Figure 2A ). This impression is confirmed by analyzing the percentage of CD33 expressed as D2-CD33, noting that D2-CD33 increases from 10.9  3.3 (n=13) in individuals homozygous for the major rs12459419C allele to 24.4  8.4% (n=13) in rs12459419C/T heterozygous individuals (mean  SD, p=1.610 -5 , two-tailed t-test) ( Figure 2A ). We confirmed these findings by analyzing expression of CD33 isoforms in RNA sequencing data from 107 AML patients available from The Cancer Genome Atlas (TCGA). We found a robust association between rs12459419 and D2-CD33 that was similar to that observed in our smaller cohort (p=4.58×10 -9 , one-way ANOVA, Figure 2B ). These findings are overall similar to our previous study in human brain that the proportion of CD33 expressed as D2-CD33 increased 10.1 percentage points per rs12459419T allele (7) . These results are also consistent with a recent report by Raj et al. who used exon arrays to show that the rs12459419T allele is associated with increased exon 2 skipping in purified human monocytes (8) .
We hypothesized that an increase in the proportion of CD33 expressed as D2- Since we also detected a CD33 isoform that retains intron 1 which is contiguous with exon 2, we hypothesized that rs12459419 may also associate with intron 1 retention.
To evaluate this hypothesis, we first quantified R1-CD33 expression by qPCR in our initial cohort of 26 AML samples. We found that R1-CD33 expression ranged from 3.9% to 32.0% of total expression (mean = 20.3%) and showed a modest increase with rs12459419T that was not significant (p=0.681, two-tailed t-test) ( Figure 4A ). Since this cohort of 26 individuals offers limited statistical power to detect an association between R1-CD33 expression and rs12459419, we proceeded to analyze expression of the R1 -CD33 expression in the TCGA cohort. We found that R1-CD33 expression ranged from 3.3% to 35.1% of total CD33 expression (mean = 13.3%). The percentage of CD33 expressed as R1-CD33 increased from 10.3 ± 4.4% (n=55) for rs12459419CC individuals to 14.5 ± 5.3% (n=42) for heterozygotes to 25.1 ± 6.8% (n=10) for rs12459419TT
individuals (mean ± SD Figure 4B ). The association between R1-CD33 and rs12459419 7 was statistically significant (p=2.17×10 -13 ) by one-way ANOVA. We attribute the results discrepancy between the 26 AML sample cohort and the 107 TCGA cohorts to the increased statistical power present in the larger TCGA cohort.
We hypothesized that R1-CD33 may undergo nonsense mediated decay (NMD) because retention of this intron is predicted to lead to a CD33 frameshift and premature translation termination; NMD commonly occurs when a ribosome encounters a termination codon upstream of an exon junction complex (15) . NMD can be detected by comparing mRNA levels in the presence and absence of a translation inhibitor. To evaluate the possibility of NMD in CD33 isoforms, we compared total CD33, D2-CD33, However, cycloheximide did not affect the levels of total CD33, D2-CD33 or R1-CD33
indicating that NMD likely does not influence CD33 isoforms ( Figure 5A-B) . The lack of NMD may be explained by recent findings that mRNA transcripts with AUG-proximal premature termination codons commonly escape NMD due to the interaction of the poly(A)-binding protein 1 (PABP) with the eukaryotic translation initiation factors eIF4G and eIF3, which block binding of the NMD-activating UPF1 to the translation complex (17) (18) (19) . In summary, R1-CD33 does not appear to undergo NMD.
We proceeded to evaluate the R1-CD33 isoform in the brain. We found that R1- Since rs3865444 and its proxy rs12459419 show an allelic dose dependence for CD33 splicing, we hypothesized that rs3865444 shows an allelic dose-dependence with AD risk. Previous reports that associated rs3865444 with AD risk used an additive model, which is the standard for GWAS (4, 5) . Here, to evaluate the effects of one and two copies of the rs3865444 minor allele on AD risk, we used a co-dominant model. We performed this analysis first with data on 9,259 AD and 8,361 non-AD DNA samples from the AD Genetics Consortium (ADGC) (4) . We found that the SNP showed a dosedependent association with AD odds (Table 1 ). This pattern was replicated in 3,455 AD and 5,006 non-AD individuals from the Mayo Clinic cohort (Table 1) . A meta-analysis of these overall data shows that rs3865444CA and rs3865444AA confer AD odds ratios of CD33 effects on microglial activation may be critical to CD33 actions in AD.
Griciuc et al. reported that ectopic CD33 overexpression in murine BV-2 cells reduces
Aß uptake while CD33 deletion decreases Aß levels in murine models of AD (11) . This action may be mediated by CD33 interaction with CD14, which appears to be an Aß receptor (25) (26) (27) , by CD33 modulation of immune activation (reviewed in (28, 29) ), or by both mechanisms. Our studies in human brain cDNA indicate that rs12459419T is associated with increased production of the atypical CD33 splice variants R1-CD33 and D2-CD33, both of which have unclear function with respect to AD mechanisms. R1-CD33 encodes an 18 amino acid CD33 signal peptide followed by a 31 amino acid peptide and premature stop codon. Since this secreted peptide has no known homology to existing proteins, its function, if any, is unclear. D2-CD33 encodes a CD33 protein lacking the IgV domain that is expressed at the cell surface ( Figure 3 and (22)).
However, in contrast to CD33, this protein does not appear to be functional in Aß phagocytosis as ectopic expression of CD33 but not D2-CD33 in BV-2 cells reduces Aß uptake (11) . A similar assay performed by Bradshaw et al. suggests that peripheral monocytes from individuals with the minor rs3865444 allele, which produce a high proportion of D2-CD33, exhibit enhanced Aß phagocytosis relative to individuals who produce more full length CD33 (30) . Hence, we predict that an increase in the proportion of CD33 expressed as R1-CD33 and D2-CD33 represents a decrease in normal CD33
function.
The finding that retention of CD33 intron 1 increases with the AD-protective minor allele of rs3865444 (and its proxy rs12459419) has implications for a model of CD33 splicing as the primary mechanism of rs3865444's modulation of AD risk.
Previously, we reported that rs12459419T is subtly associated with full length CD33 expression and strongly associated with splicing of CD33 exon 2 (7). In the present study, we report a smaller association between rs12459419 and intron 1 retention. These results combine to produce a model wherein one copy of rs12459419T decreases the production of full length CD33 mRNA by 25.2% while two copies of rs12459419T decrease the production of full length CD33 mRNA by 46.4%. This dose-dependent reduction in Lintuzumab. Extended studies to evaluate among these possibilities are underway.
In summary, we interpret our results as showing that the AD-associated CD33 polymorphism rs3865444 and its proxy rs124549419 are associated with altered exon 2 and intron 1 splicing in human brain tissue and exon 2 splicing in leukocytes from AML patients. In particular, the minor allele consistently promotes increased exon 2 deletion.
The allelic dose-dependent effects of rs12459419 on CD33 splicing are consistent with the allelic dose response for AD risk. Lastly, antibodies such as Lintuzumab may represent the means to translate these genetic findings into a pharmacologic agent.
Further studies are necessary to elucidate the actions of chronic Lintuzumab treatment on microglial function to understand their potential relevance to AD.
Materials and Methods
Human tissue samples. Human samples were obtained with appropriate institutional review board approval. Brain RNA and DNA were prepared from de-identified human brain specimens provided by the University of Kentucky AD Center Neuropathology
Core and have been previously described (38, 39) . Samples were from 31 men (16 AD and 15 non-AD) and 26 women (12 AD and 14 non-AD). The age at death for AD individuals was 81.7 ± 6.3 (mean ± SD) while the age at death of non-AD cases was 82.3 ± 8.6. AD diagnoses were made on the basis of dementia and neuropathology (amyloid plaques and neurofibrillary tangles) as previously described (40) . Leukocytes from 24 AML and two chronic myeloid leukemia patients were obtained from the University of Kentucky Markey Cancer Center, prepared by Ficoll gradients, and frozen at -80°C. RNA was extracted from these cells by using the Trizol extraction method.
Although these samples represent both leukemic and non-leukemic leukocytes, CD33
expression has been shown to be largely restricted to blasts and myeloid progenitor cells (41) . Similar results were obtained among the two CML and 24 AML cases and hence these samples are referred to as AML for simplicity.
CD33 mRNA stability. K562 cells (ATCC) were maintained in Iscove's Modified
Dulbecco's Medium with 10% fetal bovine serum, supplemented with non-essential amino acids, 50 U/ml penicillin, and 50 μg/ml streptomycin in a humidified 5% carbon dioxide atmosphere. 10 6 cells were plated in 0.9 mL media in a 24-well plate. Cells were treated with actinomycin D (5 μg/mL final concentration) with or without cycloheximide (100 μg/mL). Cells were harvested after 1, 2, 5, and 8 hours of treatment. Triplicate wells were treated for each time point. Cell suspensions were centrifuged at 300xg for 5 minutes, and RNA was extracted from cell pellets using RNEasy kits according to the manufacturer's instructions (Life Technologies).
Genotyping. Rs12459419 and rs3865444 genotypes were determined by using TaqManbased assays (Life Technologies). These two SNPs were in perfect LD in all samples.
We generally refer to rs12459419 in the quantitative studies as we have previously shown that this is the functional SNP in exon 2 splicing (7).
Analysis of gene expression in cDNA. cDNA was prepared from 1 μg total RNA using SuperScript III Reverse Transcriptase with random primers according to the manufacturer's instructions (Life Technologies). CD33 splice variants in AML patients were initially characterized by performing 30 cycles of PCR on pooled cDNA from five individuals, along with cDNA prepared from the U937 cell line. Amplification was performed from exons 1 to 3 using forward primer 5'-CTCAGACATGCCGCTGCT and reverse primer 5'-GCACCGAGGAGTGAGTAGTCC. PCR products were separated by polyacrylamide gel electrophoresis and visualized by SYBR-Gold fluorescence.
Total CD33 was quantified by using qPCR and primers corresponding to sequences within exon 4 and exon 5. D2-CD33 expression was quantified by using a forward primer corresponding to the junction of exons 1 and 3 and a reverse primer within exon 3, as described previously (7). R1-CD33 expression was quantified by using forward primer Although we recognize that these transcripts may exhibit splicing variations in exons 6 and 7, we refer to these transcripts as full length CD33 for simplicity.
qPCR was performed by using a Chromo4 thermal cycler (MJ Research) with PerfeCTa SYBR Green SuperMix (Quanta). Each 20 L sample, containing 20 ng of cDNA and 1 M of each primer, underwent an initial denaturation at 95°C for 3 minutes followed by 40 cycles of 15 second denaturation at 95°C, 40 second annealing at 60°C, and 15 second extension at 72°C . A melting curve was performed after each qPCR run to ensure specific amplification. Samples were run in parallel with standard curves to generate accurate copy numbers from C(t)s. Samples of cDNA with fewer than 5 copies of D2 -CD33 or R1-CD33 were excluded from subsequent analysis. For brain cDNAs, copy numbers were normalized to the geometric mean of ribosomal protein L32 (RPL32) and eukaryotic initiation factor 4H (EIF4H). RPL32 was quantified using primers described previously (42) . EIF4H was quantified using forward primer 5'-TCTCAGCATAAGGAGTGTACGG in exon 2 with reverse primer 5'-GGGAATCCACTTCATCGAAT in exon 3. Expression of microglial markers CD11b
and AIF was quantified as previously described (7). The geometric mean of normalized CD11b and AIF expression was used as an approximation of microglial marker expression.
To validate the nonsense mediated RNA decay experiments, we analysed cyclin T1 splice variants which were previously demonstrated to be differentially susceptible to NMD; cyclin T1 variants were PCR amplified between exons 6 and 9 as previously described (16) . PCR products were separated by polyacrylamide gel electrophoresis and stained with SYBR-Gold for 30 minutes. Fluorescence intensity was quantified (Fuji FLA-2000) to calculate relative expression of each isoform.
RNA sequencing analysis of TCGA samples. RNA sequencing data from 123 acute myeloid leukemia bone marrow samples was generated as previously described (43) . D2- Statistical analysis. In the cohort of 60 brain samples, two outliers were excluded from subsequent analysis that had normalized CD33 expression 15.5-fold higher than the median or percent R1-CD33 expression 7.7-fold higher than the median. Both of these samples came from individuals heterozygous for rs3865444 and rs12459419 and were classified as outliers according to the Grubb's test for outliers (p<0.05) (44) . The associations between normalized CD33 variant expression and rs12459419 genotype were analyzed by linear regression (SPSS) with total CD33, AD status, and rs12459419
as independent variables. The dependence of the proportion of CD33 expressed as R1-CD33 on rs12459419 genotype was calculated using the relevant  coefficient and standard error from a linear regression of the relevant isoform(s) with SNP genotype, AD status, sex, and age as independent variables. Estimated marginal means for full-length CD33 expression for each genotype were calculated using a main-effects ANOVA model with AD status, rs12459419 genotype, and sex as fixed factors and microglial marker expression and age as covariates. In the TCGA cohort, one sample was excluded from subsequent analysis that had percent D2-CD33 expression 8-fold higher than the median.
This sample was homozygous for rs12459419CC and was classified as an outlier according to Grubb's test for outliers reference (44) . 
CD33 allelic dose dependence for AD risk. The Alzheimer's Disease Genetics
Consortium (ADGC) and Mayo Clinic datasets have been described previously (45) (4).
Briefly, the ADGC dataset comprises subjects from 15 cohorts using either Affymetrix or Illumina genotyping arrays (4). Extensive quality control filtering was conducted and included MACH imputation to HapMap phase 2 (release 22) to combine SNPs across genotyping platforms (46) . Because some subjects in the Mayo dataset participated in the ADGC study, that cohort was removed from the ADGC dataset for the current analysis.
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Of the remaining 14 cohorts, rs3865444 was directly genotyped in 11 of them; results using only those 11 were consistent with those incorporating imputed genotypes.
Therefore, we report combined data from all cohorts.
The Mayo Clinic dataset contained 3455 cases and 5006 controls collected from six centers from the US and Europe as previously described (4). Direct genotyping of rs3865444 was performed using a TaqMan ® SNP genotyping assay in an ABI PRISM ® 7900HT Sequence Detection System with 384-well block module from Applied Biosystems (California, USA). First-pass genotype cluster calling was analyzed using the SDS software version 2.2.3 (Applied Biosystems, California, USA).
Association testing was carried out in PLINK (47) using additive, dominant, recessive, and co-dominant logistic regression models that corrected for appropriate covariates;
diagnosis age, APOE ɛ4 allele dose, APOE ɛ2 allele dose, sex and contributing center. Table 1 . Rs3865444 allelic dose dependence for AD risk.
These results were adjusted for PCs, cohort, sex, age and APOE genotypes. The rs3865444CA and AA genotypes are compared to rs3865444CC major allele homozygotes.
